The overproduction of peripheral serotonin, catalyzed by Tryptophan Hydroxylase 1, leads to the aggravation of many chronic and life-threatening diseases. We have developed and patented a novel class of TPH inhibitors (TPHi) to reduce the pathologically high serotonin synthesis in the periphery.